Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Document Type
Article
Publication Date
5-15-2024
Keywords
oregon; portland
Abstract
PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with
METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with
RESULTS: Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an
CONCLUSION: Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and
Clinical Institute
Cancer
Clinical Institute
Digestive Health
Specialty/Research Institute
Oncology
Specialty/Research Institute
Gastroenterology
Specialty/Research Institute
Surgery
DOI
10.1200/JCO.23.02078
